Nutritional Therapy for Graves Disease
While established guidelines for Graves disease focus on antithyroid drugs, radioiodine, and surgery as primary treatments, emerging evidence supports specific nutritional interventions—particularly optimal iodine intake and selenium supplementation—as adjunctive measures that may improve treatment outcomes and reduce recurrence rates.
Iodine Management: The Most Critical Nutritional Consideration
Optimal Iodine Intake (Not Restriction)
The traditional recommendation for strict iodine restriction in Graves disease appears to be counterproductive based on recent high-quality evidence. A prospective randomized trial demonstrated that optimal iodine supplementation during antithyroid drug therapy resulted in a 35.5% recurrence rate compared to 45.5% with iodine restriction 1. The iodine-supplemented group maintained urinary iodine concentrations of 135-162 μg/L (WHO-recommended optimal range) using approximately 10 grams of iodized salt daily 1.
Key principle: Adequate iodine intake (per WHO criteria) is associated with lower recurrence rates, higher remission rates, and better efficacy in controlling thyrotoxicosis compared to insufficient, above-requirement, or excessive iodine intake 2.
Practical Iodine Recommendations:
- Target urinary iodine concentration: 135-162 μg/L (optimal range)
- Use iodized salt (approximately 10 grams daily) rather than strict iodine-free diets
- Avoid both severe restriction AND excessive intake
- Monitor throughout the 12-18 month antithyroid drug treatment course 1
Important caveat: Most supporting studies were conducted in regions with high baseline iodine intake (300-700 μg/day), so extrapolation to iodine-deficient regions requires caution 3. However, the principle of maintaining adequate (not deficient, not excessive) iodine status appears sound.
Selenium Supplementation: Emerging Adjunctive Therapy
Selenium supplementation shows favorable effects on both biochemical markers and clinical outcomes in Graves disease 4. A 2025 scoping review of clinical trials found that selenium supplementation was associated with:
- Significant improvements in TSH, FT4, FT3 levels
- Reduction in TPOAb, TgAb, and TRAb antibody levels
- Positive clinical effects in Graves orbitopathy 4
Rationale: Selenium is essential for selenoprotein synthesis, and deficiency has been linked to increased risk and exacerbation of Graves disease and orbitopathy 4.
Practical Selenium Recommendations:
- Consider selenium supplementation as adjunctive therapy during antithyroid drug treatment
- Particularly beneficial for patients with Graves orbitopathy
- One case report noted daily consumption of 1-2 Brazil nuts (naturally high in selenium) as part of successful lifestyle intervention 5
Other Nutritional Considerations
Vitamin D: Limited Evidence
A 2023 multicenter, double-blind RCT (the DAGMAR trial) found that vitamin D supplementation (70 mcg/2800 IU daily) did NOT improve remission rates in Graves disease patients treated with antithyroid drugs. The risk of treatment failure was actually higher in the vitamin D group (42%) versus placebo (32%), though not statistically significant 6. Therefore, high-dose vitamin D supplementation cannot be recommended for Graves disease treatment 6.
Dietary Modifications (Limited Evidence)
One case report described remission through comprehensive lifestyle interventions including dairy-free and gluten-free diet, though this represents only anecdotal evidence and cannot be generalized 5.
Integration with Standard Medical Treatment
Critical point: Nutritional therapy should be viewed as adjunctive to, not replacement for, standard medical treatment. The 2018 French Society of Endocrinology guidelines clearly establish that antithyroid drugs should be prescribed first-line to restore euthyroid status regardless of subsequent treatment choice 3.
Treatment Algorithm:
- Initiate antithyroid drugs (thiamazole/methimazole or carbimazole) to restore euthyroid status 3
- Simultaneously implement optimal iodine intake (not restriction) using iodized salt to achieve urinary iodine 135-162 μg/L 1
- Consider selenium supplementation as adjunctive therapy, particularly if orbitopathy present 4
- Continue for standard 12-18 month treatment duration 3
- Monitor thyroid function monthly until euthyroid, then every 2-4 months 3
Common Pitfalls to Avoid
- Do NOT recommend strict iodine restriction: This outdated approach may actually worsen outcomes 1
- Do NOT rely on vitamin D supplementation as therapeutic intervention 6
- Do NOT present nutritional therapy as alternative to medical treatment: It is adjunctive only
- Do NOT ignore the importance of achieving euthyroid status first with antithyroid drugs before definitive treatment decisions 3